Delivery Order SPE2DB22D2211-SPE2DB25FSDNS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,594.49 to AmerisourceBergen Drug Corp for the supply of Clindamycin Phosphate 1% Lotion in 60ml quantities. This competitively awarded, firm fixed-price delivery order was issued on August 19, 2025, with an ultimate completion date of August 20, 2025. The contract carries no set-aside designation, reflecting open competition among qualified pharmaceutical vendors. AmerisourceBergen's Corporate Office in Conshohocken, Pennsylvania...
- The Defense Logistics Agency awarded a delivery order valued at $1,741.85 to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Lotion in 60ml units. This contract award, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, represents a firm fixed-price transaction with no set-aside designation. The pharmaceutical product will be delivered to the contractor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters as a...
- The Defense Logistics Agency awarded a $5,047.91 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Clindamycin Phosphate 1% Lotion (60 mL) under a firm fixed-price contract. This delivery order, which is not subject to any set-aside designation, is scheduled for completion by July 30, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions...
- The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract valued at $1,348.34 to Amerisourcebergen Drug Corp's Corporate Office Division, a subsidiary of Amerisourcebergen Corporation. The contract is for the delivery of 4,564,327,564 units of Clindamycin Phosphate 1% Lotion in 60 mL containers. This order is under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. The IDC...
- The Defense Logistics Agency awarded a delivery order valued at $1,448.80 to AmerisourceBergen Drug Corp for the supply of Clindamycin PH 1% Solution in 60ml quantities. This contract, awarded on August 15, 2025, with an ultimate completion date of August 18, 2025, represents a firm fixed price delivery order with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a non-set-aside award, this delivery order was...
- The Defense Logistics Agency awarded a $4,916.58 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Clindamycin PH 1% Solution in 60ML units. This non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by July 24, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in that same area. This delivery order is issued under...
- This federal contract award, valued at $1,534.90, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Clindamycin Phosphate 1% Lotion, a pharmaceutical product, to support the healthcare needs of the military and federal government. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Clindamycin Phosphate 1% Lotion, a prescription medication. The $1,752.05 firm-fixed-price delivery order has an ultimate completion date of August 12, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Clindamycin PH 1% Gel in a 30-gram unit, with a ceiling value of $1,206.30. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by August 21, 2025. The award represents a routine pharmaceutical procurement supporting federal medical supply requirements, with performance taking place at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Clindamycin PH 900 mg/6 ml vials with a ceiling value of $17,867.22. This firm fixed-price delivery order, which is not set-aside, will be performed at the vendor's Corporate Office in Conshohocken, Pennsylvania, with an ultimate completion date of July 23, 2025. The contract represents a routine pharmaceutical procurement under the defense medical...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSDNSDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Clindamycin Phosphate 1% Lotion in 60ml quantities under a firm fixed price contract. The award, valued at $4,684.17, was competitively awarded without set-aside designation and is scheduled for completion by August 26, 2025. AmerisourceBergen will perform this delivery order from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including delivery to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's demonstrated capability to compete and win both small-value transactions and substantial orders through the DLA Medical Supply Chain reflects its significant role as a critical pharmaceutical distributor for federal medical procurement needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.7k | 8/25/25 |